Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
The Institute of Cancer Research, London, United Kingdom.
Cancer Res Commun. 2023 Nov 17;3(11):2345-2357. doi: 10.1158/2767-9764.CRC-23-0121.
IFNγ alters the immunopeptidome presented on HLA class I (HLA-I), and its activity on cancer cells is known to be important for effective immunotherapy responses. We performed proteomic analyses of untreated and IFNγ-treated colorectal cancer patient-derived organoids and combined this with transcriptomic and HLA-I immunopeptidomics data to dissect mechanisms that lead to remodeling of the immunopeptidome through IFNγ. IFNγ-induced changes in the abundance of source proteins, switching from the constitutive to the immunoproteasome, and differential upregulation of different HLA alleles explained some, but not all, observed peptide abundance changes. By selecting for peptides which increased or decreased the most in abundance, but originated from proteins with limited abundance changes, we discovered that the amino acid composition of presented peptides also influences whether a peptide is upregulated or downregulated on HLA-I through IFNγ. The presence of proline within the peptide core was most strongly associated with peptide downregulation. This was validated in an independent dataset. Proline substitution in relevant core positions did not influence the predicted HLA-I binding affinity or stability, indicating that proline effects on peptide processing may be most relevant. Understanding the multiple factors that influence the abundance of peptides presented on HLA-I in the absence or presence of IFNγ is important to identify the best targets for antigen-specific cancer immunotherapies such as vaccines or T-cell receptor engineered therapeutics.
IFNγ remodels the HLA-I-presented immunopeptidome. We showed that peptide-specific factors influence whether a peptide is upregulated or downregulated and identified a preferential loss or downregulation of those with proline near the peptide center. This will help selecting immunotherapy target antigens which are consistently presented by cancer cells.
IFNγ 改变 HLA I 类(HLA-I)上呈现的免疫肽组,其在癌细胞上的活性对于有效的免疫治疗反应很重要。我们对未经处理和 IFNγ 处理的结直肠癌细胞源性类器官进行了蛋白质组学分析,并将其与转录组和 HLA-I 免疫肽组学数据相结合,以剖析导致 IFNγ 重塑免疫肽组的机制。IFNγ 诱导的丰度源蛋白变化,从组成型向免疫蛋白酶体转变,以及不同 HLA 等位基因的差异上调解释了一些,但不是全部,观察到的肽丰度变化。通过选择丰度增加或减少最多的肽,但来自丰度变化有限的蛋白质,我们发现呈现肽的氨基酸组成也会影响 IFNγ 是否上调或下调 HLA-I 上的肽。肽核心内脯氨酸的存在与肽下调最密切相关。这在独立数据集上得到了验证。在相关核心位置脯氨酸取代不影响预测的 HLA-I 结合亲和力或稳定性,表明脯氨酸对肽加工的影响可能最为重要。了解在不存在或存在 IFNγ 的情况下影响 HLA-I 上呈现的肽丰度的多种因素对于确定最佳的抗原特异性癌症免疫治疗靶点(如疫苗或 T 细胞受体工程治疗)非常重要。
IFNγ 重塑 HLA-I 呈现的免疫肽组。我们表明,肽特异性因素会影响肽是上调还是下调,并且确定了具有靠近肽中心的脯氨酸的肽优先丢失或下调。这将有助于选择癌症细胞始终呈现的免疫治疗靶抗原。